EMBL Australia

EMBL Australia group leaders are deeply integrated into Australian and international networks of excellence. They have established themselves as scientists and drive research and innovation in areas of national scientific priority.

In an era of transforming technologies in molecular sequencing, imaging, and artificial intelligence, there is an urgent need for skilled researchers who can bridge the gap between biomedical and computational sciences. Professor Eduardo Eyras is helping address that gap.

Dr Vaishnavi Ananthanarayanan is an innovative cell biologist whose research explores the intricate mechanisms of cellular organisation and a passionate advocate for equity, diversity and inclusion (EDI) in science.

A/Prof Maté Biro (UNSW Sydney) combines his expertise in cellular biology and advanced microscopy to improve cancer treatment efficacy, paving the way for next-generation therapies that could revolutionise the fight against cancer.

A/Prof Mikaël Martino (Monash University) is a renowned innovator in regenerative medicine, known for translating ground-breaking technologies into impactful solutions with the potential to reshape tissue repair and improve patient outcomes.

The long-term support and stability provided to EMBL Australia group leaders enables them to drive transformative advances in Australian research infrastructure, just as Professor David Lynn did.

Dr William Roman is one of the EMBL Australia group leaders pioneering groundbreaking technologies to tackle longstanding scientific challenges.

Dr Senthil Arumugam, an EMBL Australia group leader at the Monash Biomedicine Discovery Institute, is advancing Australia’s scientific infrastructure by developing world-class imaging tools – including a lattice light-sheet microscope with adaptive optics – to deliver exciting new findings.

His nine-year tenure as an EMBL Australia group leader allowed Professor Chen Davidovich to make and nurture connections with other ambitious researchers across Australia, enabling him to identify a critical gap in the nation’s research infrastructure and address it by establishing a dedicated RNA mass spectrometry platform.

Dr Qi Zhang is one of the EMBL Australia group leaders conducting ambitious, foundational research that paves the way for addressing some of the greatest health challenges in modern medicine.